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In an attempt to improve the quality of life of patients with vitreous humor disease, ophthalmologists 
began offering steroid-eluting biodegradable implants to their patients. These implants can be used as an 
alternative treatment for CRS and this is why this experimental study was carried out on rabbit maxillary 
sinuses.
Objective: This study aims to assess the histology of the mucosa of the maxillary sinuses of rabbits after 
the placement of a prednisolone-eluting biodegradable implant.
Method: Eighteen rabbits were randomly divided into two groups: group 1 - subjects had drug-eluting 
implants placed on their left maxillary sinuses; group 2 - subjects had non-drug-eluting implants placed on 
their left maxillary sinuses. The right maxillary sinuses served as the controls. After seven, 14, and 28 days 
three rabbits in each group were randomly picked to have their tissue inflammatory response assessed.
Results: Levels of mucosal inflammation were not significantly different between the groups with and 
without drug-eluting implants and the control group, or when the groups with drug-eluting implants and 
non-drug-eluting implants were compared.
Conclusion: Signs of toxicity or mucosal inflammation were not observed in the maxillary sinuses of 
rabbits given prednisolone-eluting implants or non-drug-eluting implants.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is one of the most 
common health problems to affect the population. 
Health care costs incurred in to treat this condition 
are significant. About 135 in every 1,000 people in the 
United States - or 31 million people - are affected every 
year at a total cost of 6 billion US dollars1-3.
The pathophysiology of CRS is uncertain to this 
date, and the most widely accepted theory around it 
states that it is a multifactorial chronic inflammatory 
disease possibly associated with genetic predisposition. 
Some of the related factors include: biofilm, osteitis, 
allergy, immune disorders, upper airway intrinsic factors, 
Staphylococcus aureus super antigens, eosinophilic 
inflammation produced by fungal infection, and 
metabolic disorders such as hypersensitivity to aspirin3. 
Many inflammatory patterns are believed to be involved 
with CRS and that they may differ depending on the 
postoperative prognosis3,4.
Various therapies have been suggested for 
patients with CRS. High grade evidence indicates that 
topical nasal steroids, systemic steroids, and low-dosage 
macrolides on long term regimens are effective in 
managing CRS. Functional endoscopic sinus surgery 
(FESS) may be an alternative to patients failing to 
respond to the medical treatment5.
The lack of knowledge on the actual 
pathophysiology of CRS translates into difficulties 
finding a curative therapy, thus depositing additional 
importance on patient compliance and treatment 
preferences. Mode of administration, type of medication, 
total cost of treatment and side effects must always be 
considered.
Intraocular injections of steroids are a frequent 
nuisance in the lives of patients with vitreous humor 
disease. In order to spare them from the injections, 
ophthalmologists have been offering steroid-eluting 
biodegradable implants to their patients6,7.
The placement of a biodegradable implant on the 
target organ allows better control of drug administration 
and the attainment of therapeutical levels with lower 
drug concentrations, virtually eliminating adverse 
systemic effects8-10. Non-biodegradable implants have 
also been used to the same end with promising results. 
Nonetheless, they require a second procedure to 
remove the implant after all the drug has been released8.
Biodegradable implants are prepared from 
various polymers which, in vivo, must ideally degrade 
for enough time to allow controlled drug release and 
thus produce biocompatible metabolites that can be 
easily washed away11.
The most frequently used biodegradable 
polymers are polyesters such as caprolactone, o 
polylactic acid (PLA) and various lactic and glycolic 
acid copolymer types (PLGA), the latter two being 
extensively used12.
PLA and the different types of PLGA have 
been widely used and studied in prolonged drug 
delivery systems (PDRS) in various human tissues. 
Biodegradation of these polymers occurs by erosion, 
cleavage of the polymer chain by hydrolysis with the 
consequent release of lactic and glycolic acids. These 
acids are natural metabolites and are eliminated by the 
Krebs cycle in the form of carbon dioxide and water 
(Figure 1)13.
Figure 1. Hydrolysis mechanism of PLA, PGA or PLGA (adapted from 
Merkli et al.13).
The presence of a methyl (CH3) group in the 
lactic acid chain of PLGA confers greater hydrophobicity 
to the biomaterial when compared to byproducts 
containing greater amounts of glycolic acid (PGA). 
Therefore, PGA is quite sensitive to hydrolysis and unfit 
to be used in PDRS. As it concerns PLGA, the greater 
the levels of lactic acid, the more hydrophobic the 
copolymer, the less water it absorbs, and the slower it 
degrades. Additionally, molecular weight and degree 
of crystallinity may impact the mechanical properties, 
hydrolytic capacity, and degradation rates of these 
polymers9.
PDRS using PLGA with high contents of lactic 
acid - characterized by lower degradation rates - may 
result in systems in which drug release occurs for 
periods of time as long as three years, depending on 
production parameters and external variables related to 
the tissue in which it is placed14. Thus, the development 
of these systems may mean significant progress, 
once they are able to keep drug concentrations on 
the desired site within therapeutical levels for a long 
period of time15-19. Many drugs may be conveyed 
using implants, such as antibiotics, antiviral drugs, 
chemotherapy agents, and steroids, with satisfactory 
results in eye care according to recently published 
papers, in which implant degradation in the vitreous 
did not lead to damage to eye tissues6,8,13.
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Implants may become a good alternative 
treatment to CRS, as once in contact with the paranasal 
sinus mucosa they may facilitate treatment and 
patient compliance, acting as a substitute for the daily 
application of topical steroids. Therefore, this study 
aims to assess the histology of the mucosa of the 
maxillary sinuses of rabbits after the placement of a 
prednisolone-eluting biodegradable implant.
METHOD
This study included 18 female New Zealand 
rabbits weighing between 2.5 and 3.5 Kg kept in cages 
in the animal lab of the Ribeirão Preto Medical School 
of the University of São Paulo (FMRP-USP). The 18 
subjects were randomly divided into two groups.
In the preparation of the biodegradable implants, 
prednisolone and PLGA (75:25) were weighed on a ratio 
of 21-26/79-74% and then solubilized on proper solvent 
and distilled water. The solution was then filtered 
using a sterile 0.2 mm filter under laminar flow. Next 
it was frozen dried, and used to prepare hot-molded 
rod-shaped implants. The implants weighed between 
0.9 and 1.2 mg, measured 4.5 to 6.0 mm in length, 
and had diameters ranging between 0.4 and 0.5 mm 
(Figure 2A). The low coefficient of variation between 
the implants was indicative of the reproducibility of 
the employed technique. Macroscopically, the implants 
were similar smooth monolithic systems with steroids 
scattered within the polymer matrix. The surface and 
outer shape of the implants were examined on an 
scanning electron microscope (SEM). Surface images 
were captured at magnification powers ranging from 
250 to 5,000 times (Figure 2B-C).
Figure 2. A: Macroscopic view of biodegradable implant; B: SEM 
image of biodegradable implant; 250x magnification; C: SEM images 
of biodegradable implant; 5000x magnification.
Surgical Procedure
The rabbits were anesthetized with intramuscular 
xylazine hydrochloride (20 mg/Kg) and ketamine 
hydrochloride (10 mg/Kg). The nasal dorsum of the 
rabbits was cleaned with iodine. A sagittal incision of 
approximately 5 cm on the midline of the nasal dorsum 
down to the periosteum was performed (Figure 3A-B). 
The periostea on both sides of the nasal dorsum were 
Figure 3. A: Sagittal incision on rabbit dorsum; B: Five-centimeter 
sagittal incision to periosteum; C: Detachment of periosteum to expose 
bone suture on the midline and anterior walls of both maxillary sinuses; 
D: Rectangular bone-mucosal flap produced with chisel and hammer; 
E: Placement of prednisolone-eluting biodegradable implant in left 
maxillary sinus; F: Bone flap in place.
detached with a Paparella ear tube to expose the bone 
suture on the midline and the anterior wall of both 
maxillary sinuses (Figure 3C). Chisel and hammer were 
used to produce 25x8 mm rectangular bone-mucosal 
flaps on the anterior wall of both maxillary sinuses, 
with the larger axis running parallel to the midline bone 
suture. The medial border of the flap was 3 mm away 
from the midline bone suture and the upper border 3 
to 5 mm below the frontal-maxillary suture (Figure 3D). 
The macroscopic aspect of the maxillary sinus mucosa 
was observed with the aid of a headlight.
The rabbits were divided into two groups. Group 
1 subjects had prednisolone-eluting biodegradable 
implants placed on their left maxillary sinuses; the 
same procedure was carried out in their right maxillary 
sinuses, but no implants were inserted (Figure 3E); 
Group 2 had non-drug-eluting biodegradable implants 
placed on their left maxillary sinuses; the same 
procedure was carried out in their right maxillary 
sinuses, but no implants were inserted.
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The right maxillary sinuses of both groups were 
used as controls. After this stage, the bone flaps were 
put in place again to mitigate invasion on sinus tissue 
and the subjects’ skin was stitched closed with nylon 
4-0 wire to ensure tight contact between the periosteum 
and subcutaneous tissue (Figure 3F). The site of the 
procedure was again cleaned with iodine and subjects 
were administered intramuscular ketoprofen (10mg/
kg) for two days and enrofloxacin (0,1 ml/kg) for 
three days.
The experimental protocol employed in this 
study was approved by the Animal research Ethics 
Committee at FMRP-USP (permit nº 132/2010).
After seven, 14, and 28 days three rabbits were 
randomly picked from each group and slaughtered 
under general anesthesia as described above. Their 
facial mesostructure was removed in a block resection 
and placed in 10% formaldehyde for further histological 
analysis (Figure 4A-B). For histology analysis purposes, 
the specimens were placed in a formaldehyde solution 
(10% w/v) and were left for six days in a solution of 
nitric acid (5% w/v) for decalcification. Serial cross-
sectional slices from the nose to the skull were made 
every two centimeters (Figure 4C-E); then they were 
dehydrated, clarified, and embedded in paraffin. Next, 
the specimens were cut on a microtome in 5 µm thick 
slices, and stained in hematoxylin-eosin to assess tissue 
inflammatory response patterns.
The slides were analyzed by the same pathologist 
using a semiquantitative approach. The examiner was 
blinded for the groups to which the slides belonged, and 
rated them as per the adopted criteria for inflammation: 
0 = no inflammation; 1 = mild inflammation (scattered 
inflammatory cells, no evident epithelial lesion); 2 = 
moderate inflammation (diffuse inflammatory infiltrate 
in the lamina propria, no formation of inflammatory 
aggregates, presence of focal epithelial cell lesion 
characterized by disorganized ruptured epithelial cells); 
3 = severe inflammation (dense diffuse inflammatory 
infiltrate with formation of inflammatory aggregates 
and diffuse epithelial cell lesion characterized by 
disorganized ruptured epithelial cells)20.
Software package SPSS (Statistical Package for 
Social Sciences) release 19.0 was used to process 
raw data and produce statistical results. A statistical 
significance level of 5% (0.05) was adopted in statistical 
tests.
RESULTS
Seven rabbits in Group 1 (prednisolone-eluting 
biodegradable implants on left maxillary sinuses) did 
not present signs of mucosal inflammation; two were 
Figure 4. A-B: Dehydrated facial mesostructure in 10% formaldehyde; 
C-E: Serial cross-sectional slices from nose to skull every two centimeters.
slaughtered on day 7, three on day 14, and two on day 
28 after implantation. Only two, one slaughtered on day 
7 and another on day 28 after implantation, had mild 
and moderate inflammation respectively (Figure 5). 
Severe inflammation was observed in the right maxillary 
sinuses (control side) of two rabbits slaughtered 
seven days after implantation, whereas the rest of 
the group had no signs of inflammation (Table 1). 
Mild mucosal inflammation was observed in one of 
the rabbits slaughtered seven days after implantation 
and in two slaughtered on day 14 in Group 2 (non-
drug-eluting biodegradable implants on left maxillary 
sinuses). Moderate mucosal inflammation was seen in 
two rabbits slaughtered on days 7 and 28 respectively 
(Figure 5A-B). Only one subject slaughtered on day 28 
had severe inflammation. The remaining subjects did 
not have signs of inflammation. Four rabbits in Group 
2 (controls) did not have right maxillary sinus mucosal 
inflammation. Mild inflammation was observed in three 
subjects; moderate inflammation in one and severe in 
another slaughtered on day 28 (Table 2).
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Table 1. Histological assessment of inflammation on mucosas 
of rabbits in Group 1.
Subjects Right maxillary sinus (control) Left maxillary sinus Time to slaughter
C13 0 (I + P) 0 7 days
C17 0 (I + P) 1 7 days
C18 0 (I + P) 0 7 days
C1 0 (I + P) 0 14 days
C2 0 (I + P) 0 14 days
C3 0 (I + P) 0 14 days
C6 3 (I + P) 2 28 days
C7 3 (I + P) 0 28 days
C8 0 (I + P) 0 28 day
0: no inflammation; 1: mild inflammation; 2: moderate inflammation; 
3: severe inflammation; (I+P): prednisolone-eluting biodegradable 
implant.
Table 2. Histological assessment of inflammation on mucosas 
of rabbits in Group 2.
Subjects Right maxillary sinus (control) Left maxillary sinus Time to slaughter
C14 0 (I) 1 7 days
C15 1 (I) 0 7 days
C16 0 (I) 2 7 days
C10 0 (I) 0 14 days
C11 1 (I) 1 14 days
C12 1 (I) 1 14 days
C4 0 (I) 0 28 days
C5 2 (I) 2 28 days
C9 3 (I) 3 28 days
0: no inflammation; 1: mild inflammation; 2: moderate inflammation; 3: 
severe inflammation; (I): biodegradable implant without prednisolone.
Table 3. Inflammation pattern in controls and sinuses with 
biodegradable implants.
Controls
Sinuses with biodegradable implants
Total
N Y
N
8 3 11
44.40% 16.70% 61.10%
Y
2 5 7
11.10% 27.80% 38.90%
Total
10 8 18
55.60% 44.40% 100.00%
p > 0.999.
Table 4. Inflammation pattern in maxillary sinuses with and 
without prednisolone.
Implants
Inflammation
Total
N Y
P
7 2 9
77.80% 22.20% 100.00%
Non-P
3 6 9
33.30% 66.70% 100.00%
Total
10 8 18
55.60% 44.40% 100.00%
p = 0.077.
No statistically significant differences were noted 
on inflammatory patterns when the mucosas of the 
maxillary sinuses receiving the implants with and 
without prednisolone were compared to their controls.
Description and comparison between 
implants with and without steroids
Fisher’s exact test was used to verify possible 
differences between implants with and without steroids 
for variable ‘inflammation’ in two categories (Table 4). 
A trend indicative of lesser mucosal inflammation in the 
rabbits given the implant with steroids was found when 
the mucosas of the maxillary sinuses of rabbits receiving 
the implants with prednisolone were compared to the 
mucosas of the subjects receiving the implants without 
prednisolone, as the calculated p-value sat between 5% 
(0.050) and 10% (0.100).
Figure 5. A: Left maxillary sinus mucosa (rabbit 1) without inflamma-
tion or sings of toxicity (HE stain, 10x magnification); B: Left maxillary 
sinus mucosa (rabbit 5) with moderate inflammation (HE stain, 10x 
magnification).
Statistical Results
Description and comparison between 
sample members
McNemar’s test was applied to verify possible 
differences between both investigated sides for 
variable ‘inflammation’ in two categories (Table 3). 
Effect of variable ‘slaughter time’
A verisimilitude ratio test was applied to verify 
possible differences between the three times at 
which the rabbits were slaughtered when compared 
concurrently for the variables of interest (Tables 5 and 6). 
No statistically significant differences were found in 
mucosal inflammation when the groups receiving 
implants with and without steroids were compared to 
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On a first study done in 20067 and in another two 
carried out in 2007 and 2008, Fialho et al.8,10 showed 
that steroid-eluting biodegradable implants placed on 
the vitreous of rabbits’ eyes did not lead to toxicity or 
significant inflammatory response, as similarly seen 
in the mucosas of the paranasal sinuses of the rabbits 
included in this study. However, it is worthy noting that 
in the ENT area this is the first study to describe the 
use of biodegradable implants as a means to provide 
controlled release of medication (prednisolone) onto 
paranasal sinuses.
This study was limited to assessing the 
inflammation these implants could introduce to the 
mucosas of the maxillary sinuses of rabbits. Other 
parameters need to be further studied, such as the 
proper concentration of the drug on the implant and 
the ideal amount of polymer to allow for optimal 
implant degradation and, consequently, the amount 
of medication to be released onto the target organ, 
the best implant size to reach each specific goal, 
and how much drug could be absorbed systemically. 
This is key information for the future development of 
implants that can be safely placed in humans as seen 
in ophthalmic care.
This study has been the first step toward the 
development of a possible treatment for CRS.
CONCLUSION
Although this is a preliminary study, we may 
state that the implants with and without steroids did 
not cause toxicity or inflammation to the maxillary sinus 
mucosas of rabbits.
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